A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinumrefractory small cell lung cancer patients

Authors

Lauren Averett Byers, The University of Texas MD Anderson Cancer Center
Leora Horn, Vanderbilt University
Jitendra Ghandi, Associates in Oncology and Hematology
Goetz Kloecker, University of Louisville
Taofeek Owonikoko, Emory University
Saiama Naheed Waqar, Washington University School of Medicine in St. Louis
Maciej Krzakowski, Centrum Onkologii-Instytut
Robert J. Cardnell, The University of Texas MD Anderson Cancer Center
Junya Fujimoto, The University of Texas MD Anderson Cancer Center
Pietro Taverna, Astex Pharmaceuticals, Inc.
Mohammad Azab, Astex Pharmaceuticals, Inc.
Daivd Ross Camidge, University of Colorado Cancer Center

Journal

Oncotarget

Publication Date

2017

Volume

8

Issue

46

Inclusive Pages

81441-81454

Document Type

Open Access Publication

DOI

10.18632/oncotarget.19888

Rights and Permissions

Byers, L. A., Horn, L., Ghandi, J., Kloecker, G., Owonikoko, T., Waqar, S. N., . . . Camidge, D. R. (2017). A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinumrefractory small cell lung cancer patients. Oncotarget, 8(46), 81441-81454. doi:10.18632/oncotarget.19888

Recommended Citation

Byers, Lauren Averett; Horn, Leora; Ghandi, Jitendra; Kloecker, Goetz; Owonikoko, Taofeek; Waqar, Saiama Naheed; Krzakowski, Maciej; Cardnell, Robert J.; Fujimoto, Junya; Taverna, Pietro; Azab, Mohammad; and Camidge, Daivd Ross, "A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinumrefractory small cell lung cancer patients." Oncotarget. 8, 46. 81441-81454. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6266